Patents Examined by Kristin Vajda
  • Patent number: 10981869
    Abstract: The invention provides bridged diindole compounds, related pharmaceutical compositions and methods of use thereof, for the prevention, palliation and/or treatment of nervous system disorders.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: April 20, 2021
    Assignee: Rhode Island Board of Education
    Inventors: Kyle Robert Scully, Roberta S. King, David R. Worthen
  • Patent number: 10981901
    Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: April 20, 2021
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Joseph J. Romano, Jianxing Kang
  • Patent number: 10981924
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: April 20, 2021
    Assignee: AbbVie Inc.
    Inventors: Jayanthy Jayanth, Ben Klünder, Mohamed-Eslam Mohamed, Ahmed A. Othman, Patrick J. Marroum, Peter T. Mayer
  • Patent number: 10981923
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: April 20, 2021
    Assignee: AbbVie Inc.
    Inventors: Ayman Allian, Thomas B. Borchardt, Jayanthy Jayanth, Patrick J. Marroum, Peter T. Mayer, Mathew M. Mulhern, Fredrik Lars Nordstrom, Ahmad Y. Sheikh
  • Patent number: 10980777
    Abstract: The present application relates to compounds of formula (I), wherein A, R, R1, and R2 are as defined in the specification, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: April 20, 2021
    Assignee: Istituto Europeo di Oncologia S.r.l.
    Inventors: Mario Varasi, Anna Cappa, Paola Vianello, Loris Moretti, Luca Sartori, Ciro Mercurio
  • Patent number: 10975016
    Abstract: The present disclosure provides, in part, a solvent compound for use as a substitute for a glycol ether, an alkyl ether of diethylene glycol, ethylene glycol or propylene glycol.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: April 13, 2021
    Inventors: David A. Pasin, Joseph Mitchell Clarkson, Laurel L. Schafer
  • Patent number: 10975296
    Abstract: An electrochromic compound represented by the following formula (1) is provided: where each of R1 to R9 and Ar1 to Ar6 independently represents one of a hydrogen atom, a halogen atom, a monovalent organic group, a group in which two or more aryl and/or heteroaryl groups are bound to each other via a covalent bond, a group in which two or more aryl and/or heteroaryl groups are condensed with each other to form a ring, and a polymerizable functional group; and at least one of Ar1 to Ar6 represents an aryl group, a heteroaryl group, a group in which two or more aryl and/or heteroaryl groups are bound to each other via a covalent bond, or a group in which at least two aryl or heteroaryl groups are condensed with each other to form a ring.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: April 13, 2021
    Assignee: Ricoh Company, Ltd.
    Inventors: Daisuke Goto, Toshiya Sagisaka, Satoshi Yamamoto, Masato Shinoda, Mamiko Inoue
  • Patent number: 10975023
    Abstract: The present invention provides compounds useful in treating or preventing inflammation acne, bacterial conditions and promoting the appearance of healthy skin and compositions including these compounds.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: April 13, 2021
    Assignee: Signum Biosciences, Inc.
    Inventors: Michael Voronkov, Edwardo Perez, Jason Healy, Jose Fernandez
  • Patent number: 10968231
    Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: April 6, 2021
    Assignees: SCOHIA PHARMA, INC., TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Seiji Miwatashi, Yasufumi Miyamoto, Koji Watanabe, Yayoi Nakayama, Yuko Hitomi, Jumpei Aida, Nobuyuki Takakura, Hideki Furukawa, Naoyoshi Noguchi, Yasuhiro Hirata, Shizuo Kasai, Toshitake Kobayashi, Tsuyoshi Maekawa, Satoshi Sasaki, Shigemitsu Matsumoto
  • Patent number: 10968209
    Abstract: The present invention relates to a novel compound useful as a TRPV4 antagonist, specifically the compound 1-(((5S,7R)-3-(5-cyclopropylpyrazin-2-yl)-7-hydroxy-2-oxo-1-oxa-3-azaspiro[4.5]decan-7-yl)methyl)-1H-benzo[d]imidazole-6-carbonitrile, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compound.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: April 6, 2021
    Inventors: Patrick Stoy, Carl A. Brooks, Guosen Ye
  • Patent number: 10968225
    Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular to modulate CFTR protein or ABC protein activities.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: April 6, 2021
    Inventors: Tiziano Bandiera, Fabio Bertozzi, Paolo Di Fruscia, Federico Sorana, Francesco Berti, Alejandra Rodriguez Gimeno, Emanuela Caci, Loretta Ferrera, Nicoletta Pedemonte, Luis Juan Vicente Galietta
  • Patent number: 10968172
    Abstract: The application relates to phenyl- or naphthylsulfonamide derivatives of the structural formula (I). The compounds are described as inhibitors of USP30 (ubiquitin specific peptidase 30) useful for the treatment of conditions involving mitochondrial defects including neurodegenerative diseases such as Alzheimer's and Parkinson's or a neoplastic disease such as leukemia.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: April 6, 2021
    Assignee: Mitobridge, Inc.
    Inventors: Arthur Kluge, Bharat Lagu, Pranab Maiti, Sunil Kumar Panigrahi
  • Patent number: 10959970
    Abstract: Disclosed herein are methods for treating hair related disorders, including compounds that may be specific or modulate PPAR receptors.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: March 30, 2021
    Assignee: Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Patent number: 10961277
    Abstract: The invention relates to novel methods for synthesizing amanitin derivatives having a hydroxy group attached to the central tryptophan moiety. The invention furthermore relates to novel amanitin derivatives having a hydroxy group attached to position 4?, 5? or 7? of the central tryptophan moiety, novel conjugates of such amanitin derivatives, and pharmaceutical compositions comprising such conjugates.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: March 30, 2021
    Assignee: Heidelberg Pharma Research GmbH
    Inventors: Christian Lutz, Werner Simon, Susanne Werner-Simon, Christoph Müller, Torsten Hechler, Michael Kulke
  • Patent number: 10954229
    Abstract: The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: March 23, 2021
    Assignee: MANKIND PHARMA LTD.
    Inventors: Rakesh Ishwar Patil, Jeevan Verma, Puneet Kumar, Amol Pandurang Gunjal, Himanshu Rai, Santosh Kumar Rai, Anil Kumar
  • Patent number: 10946017
    Abstract: The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) TBK1. In particular, the present invention is directed to compounds, which contain on one end an E3 ubiquitin ligase binding moiety which binds to an E3 ubiquitin ligase and on the other end a moiety which binds TBK1 such that TBK1 is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of TBK1. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of TBK1.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: March 16, 2021
    Assignee: ARVINAS OPERATIONS, INC.
    Inventors: Andrew P. Crew, Jing Wang, Hanqing Dong, Yimin Qian
  • Patent number: 10946013
    Abstract: The present invention relates to use of small organic compounds interacting with the Voltage-Dependent Anion Channel (VDAC) for the treatment of diseases associated with central nervous system (CNS) disorders, including psychotic disorders, mood disorders, neurodegenerative diseases. In particular the present invention relates to the use of substituted piperazine- and piperidine-derivatives and pharmaceutical compositions comprising same for the treatment of psychotic disorders including schizophrenia, mood disorders, and neurodegenerative diseases.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: March 16, 2021
    Assignee: The National Institute for Biotechnology in the Negev Ltd.
    Inventors: Varda Shoshan-Barmatz, Arie Lev Gruzman
  • Patent number: 10947219
    Abstract: The present invention relates an enantioselective process for the manufacture of a compound of formula (D) wherein ring A, RB2 and RB3 are as defined in claim 1.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: March 16, 2021
    Assignee: SYNGENTA CROP PROTECTION AG
    Inventors: James Alan Morris, Sally Elizabeth Russell, Sean Ng
  • Patent number: 10941117
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: March 9, 2021
    Assignees: GALAPAGOS NV, LES LABORATORIES SERVIER
    Inventors: Franck Laurent Brebion, Luke Jonathan Alvey, David Amantini, Frédéric André De Ceuninck, Pierre Marc Marie Joseph Deprez, Romain Luc Marie Gosmini, Hélène Marie Jary, Christophe Peixoto, Iuliana Ecaterina Pop-Botez, Marie Laurence Claire Varin
  • Patent number: 10934255
    Abstract: Compounds that inhibit histone (HDACI) and/or activate Nrf2 and HIF, and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC and/or activation of Nrf2 and HIF provide a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: March 2, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Irina Gaisina, Alan Kozikowski